Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile

Summary

Phase 2 clinical trial in adults previously vaccinated against SARS-CoV-2 in Chile with an initial schedule of two doses of CoronaVac® plus two booster doses with different vaccines. Subjects will randomly receive a third booster dose with Omicron, trivalent, or CoronaVac® vaccine. The humoral immunogenicity against COVID-19 will be compared in subjects that received the Omicron or the Trivalent vaccines with subjects that received CoronaVac® to determine the superiority of the two candidate vaccines versus CoronaVac®. Subjects will be followed for 6 months after the booster dose administration.

Timeline

Start

2022-11-28

Primary completion

2023-10-26

Completion

2023-10-26

Publications

• Mendez C, Rodriguez-Guilarte L, Palacios PA, Gutierrez-Vera C, Roman F, Moreno-Tapia D, Rios M, Reyes A, Cancino FA, Otero FF, Zurita C, Rivera D, Cabrera A, Duarte LF, Urzua M, Iturriaga C, Rojas A, Perez CM, Redlich AS, Fasce RA, Fernandez J, Mora J, Ramirez E, Dominguez A, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W, Goldbatt D, Johnson M; CoronaVarCL study group; Gonzalez-Aramundiz JV, Alvarez-Figueroa MJ, Abarca K, Carreno LJ, Gonzalez PA, Kalergis AM, Penaloza HF, Bueno SM. A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity. BMC Med. 2025 Dec 15;24(1):37. doi: 10.1186/s12916-025-04535-8.

Drugs

Indications